From 31 May till 4 June 2024: HIGHLIGHTS FROM ASCO – GI
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2024 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Daily highlights in GI
Dr Willem Lybaert, a medical oncologist at the VITAZ Sint-Niklaas & University Hospital Antwerp gives a nice summary of the oral abstract session on gastroesophageal, pancreatic and hepatobiliary tumours from
Prof Hans Prenen, a medical oncologist at the University Hospital Antwerp, Belgium, provided a comprehensive overview of critical studies presented at ASCO 2024 in the rapid oral abstract session on
Prof. Alain Hendlisz, a digestive oncologist at the Institut Jules Bordet in Brussels, Belgium, provided a comprehensive overview of key studies presented at ASCO 2024 in the rapid oral abstract
Prof Eric Van Cutsem, a digestive oncologist at University Hospitals, Belgium, provided a comprehensive overview of key studies presented at ASCO 2024 in the session on colorectal and anal cancer.
In-depth stories about GI
Prof Prenen highlights one significant trial, the Ragnar trial, which resulted at ASCO 2024 in three posters for the trial site at the University Hospital Antwerp. The Ragnar trial is
In this interview, Prof Arndt Vogel, a GI oncologist from Toronto, discusses updates from the ASCO meeting on the KEYNOTE-966 study, which evaluated pembrolizumab in combination with gemcitabine and cisplatin
Study 22 was a phase I/II trial evaluating different immune checkpoint inhibitor (ICI)-based regimens in patients with unresectable hepatocellular carcinoma (HCC). The study showed higher rates of objective response (ORR)
During the 2024 ASCO GU meeting earlier this year, the CheckMate 8HW study demonstrated an unprecedented benefit in progression-free survival (PFS) for patients with MSI-high/dMMR unresectable or metastatic colorectal cancer
Previously, the phase III EMERALD-1 trial showed that a regimen combining transarterial chemoembolization (TACE) with durvalumab (D) and bevacizumab (B) resulted in a statistically significant and clinically meaningful improvement in
Prof Dr Jeroen Dekervel from UZ Leuven (Belgium) and Prof Dr Florian Lordick from the University of Leipzig (Germany) discuss the ESOPEC trial.
The ESOPEC trial focused on patients
GI poster selection
The KEYNOTE-859 study investigated the efficacy of pembrolizumab combined with chemotherapy versus placebo plus chemotherapy in patients with HER2-negative gastric/gastroesophageal junction (G/GEJ) cancer. With a median follow-up of 41.6 months,
Mitazalimab, a human CD40 agonistic IgG1 antibody, shows promise by reducing immune suppression, sensitising tumours to chemotherapy, and inducing long-lasting anti-tumour T-cell responses. The OPTIMIZE-1 study is a Phase 1b/2